Celiac Disease Remission With Tofacitinib: A Case Report
Authors: Lucas Wauters, Tim Vanuytsel, Martin Hiele
Journal: Annals of Internal Medicine (2020)

Letters6 October 2020Celiac Disease Remission With Tofacitinib: A Case ReportLucas Wauters, MD, Tim Vanuytsel, MD, PhD, and Martin Hiele, MD, PhDLucas Wauters, MDUniversity Hospitals Leuven, Leuven, Belgium (L.W., T.V., M.H.)Search for more papers by this author, Tim Vanuytsel, MD, PhDUniversity Hospitals Leuven, Leuven, Belgium (L.W., T.V., M.H.)Search for more papers by this author, and Martin Hiele, MD, PhDUniversity Hospitals Leuven, Leuven, Belgium (L.W., T.V., M.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-0497 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Celiac disease is an autoimmune and gluten-induced enteropathy with a worldwide prevalence of around 1%. The only proven treatment is strict and lifelong adherence to a gluten-free diet (1). Although dietary adherence is crucial for mucosal healing and prevention of long-term complications, complete avoidance of gluten is difficult for even the most committed patients. Nondietary treatments for celiac disease have no established efficacy.Objective: To report what we believe to be the first case of serologic and histologic remission of adult celiac disease with tofacitinib despite a gluten-containing diet.Case Report: A male patient with a histologically and serologically ...References1. Rubin JE, Crowe SE. Celiac disease. Ann Intern Med. 2020;172:ITC1-ITC16. [PMID: 31905394]. doi:10.7326/AITC202001070 LinkGoogle Scholar2. Sandborn WJ, Su C, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-36. [PMID: 28467869] doi:10.1056/NEJMoa1606910 CrossrefMedlineGoogle Scholar3. Yokoyama S, Perera PY, Waldmann TA, et al. Tofacitinib, a Janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol. 2013;33:586-94. [PMID: 23269601] doi:10.1007/s10875-012-9849-y CrossrefMedlineGoogle Scholar4. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366:1515-25. [PMID: 22512484] doi:10.1056/NEJMra1103442 CrossrefMedlineGoogle Scholar5. Corazza GR, Andreani ML, Venturo N, et al. Celiac disease and alopecia areata: report of a new association. Gastroenterology. 1995;109:1333-7. [PMID: 7557104] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University Hospitals Leuven, Leuven, Belgium (L.W., T.V., M.H.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-0497.Corresponding Author: Lucas Wauters, MD, Department of Gastroenterology and Hepatology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium; e-mail, lucas.[email protected]be.This article was published at Annals.org on 28 July 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNormalization of duodenal mucosa after treatment with Janus kinase (JAK) inhibitor in refractory celiac disease type 2Successful novel use of tofacitinib for type II refractory coeliac disease 6 October 2020Volume 173, Issue 7Page: 585KeywordsCeliac diseaseCreatine kinaseDietDisclosureDrugsEnteropathiesGlutenKinase inhibitorsLipidsMouse models ePublished: 28 July 2020 Issue Published: 6 October 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...